UK ONCOLOGY FORUM 2024
Thursday 13th June - Friday 14th June 2024
​
Registration is now open for the 2024 UK Oncology Forum at
DoubleTree by Hilton Brighton Metropole, Kings Rd, Brighton and Hove, Brighton BN1 2FU
Click here now to register https://oncology-forum.co.uk/register/
The meeting remains FREE (no registration fee) to all UK NHS cancer healthcare professionals. CME has been applied for. We have attracted a team of leading cancer experts, and we will deliver an excellent programme for 2024, including important ASCO high lights and insights.
NOTCH continue to collaborate with our friends and colleagues at UKOF and we will be running our AGM Thursday 13th June 10 - 12. More details to follow.
We suggest that you book your travel to arrive in Brighton no later than 10am – so that you can gain maximum use of the meeting. Please visit the UK Oncology Forum website on the Programme/Meeting tab where there is a useful information guide which provides useful links for travel and accommodation - https://oncology-forum.co.uk/programme-meeting/
Unfortunately travel and accommodation cannot be supported, you will need to arrange and pay for this yourself. This year we have limited places – to avoid disappointment, please register ASAP.
Thursday 13th June
08:30hrs – 12:00hrs – Fringe meetings (please regularly look at the UKOF24 website for updates)
10:30am – 11:15hrs – there will be excellent Industry symposiums – we will be giving more information soon (please organise travel to arrive in Brighton for 10am)
11:45hrs – 12:45hrs – Novartis Platinum Sponsor Breast Cancer Symposium with lunch
12:00hrs – 12:55hrs – Exhibition will open with hot buffet lunch
13:00hrs - 2023 UK Oncology Forum opens
Friday 14h June
08:00hrs Industry symposiums
09:00hrs Day 2 UKOF
12:00hrs Keynote closing speaker
13:00hrs Symposiums and lunch - there will be excellent Industry symposiums – we will be giving more information soon
14:00hrs UKOF Closes
Please arrange return travel after 14:15hrs
We look forward to welcoming you to Brighton.
With kindest regards
Professor Plummer & the UKOF Faculty
PS PLEASE CHECK YOUR SPAM FOLDER FOR THE AUTOMATED REGISTRATION RESPONSE – FOLLOW US ON TWITTER @OncologyForum #UKOF24.
NO SPONSORS HAVE HAD ANY INPUT IN TO THE MEETINGS OR ON THE SPEAKER CHOICES. OPEN TO HEALTHCARE PROFESSIONALS ONLY. THE MEETINGS WILL RUN STRICTLY TO THE ABPI CODE OF PRACTICE.
ANNUAL TRAINEE ONCOLOGY MEETING (ATOM) 2024
Saturday 15th June - Sunday 16th June 2024
​
The Royal College of Radiologists are again hosting this annual conference for clinical oncology trainees, this time in the south west city of Exeter.
​
Packed full of educational content (SABR for oligometastatic disease, cancer considerations for LGBTQ population, palliative radiotherapy, career pathways, exams and much more) and networking opportunities (course dinner, guided run, refreshments all included), this promises to be an excellent event.
​
For more details and to book your place, click on the button below.
FRANCIS CRICKÂ INSTITUTE
POST-DOCTORAL FELLOWSHIPS
The Francis Crick institute are advertising post-doctoral fellowship opportunities for clinical academics.
​
For more information, visit their website at www.crick.ac.uk/careers-and-study/clinical-fellows or click on the button below to view the flyer advertising the posts
​
Application Deadline: 30th April 2024
MARGARET SPITTLE RESEARCH FELLOWSHIPS, UCLH
Two exciting one-year research fellowships are now being advertised at The University College Hospitals, London
​
Post 1 – Clinical Oncology – Gastrointestinal (Photons, Protons)
Clinical and Research Focus: Join our dynamic team in the cutting-edge field of Clinical Oncology, specializing in Gastrointestinal (GI) malignancies. This position offers a unique opportunity to delve into both clinical practice and research, under the mentorship of renowned experts in the field.
Clinical Responsibilities: Under the supervision of Dr. Douglas Brand and Prof. Maria Hawkins, GI Clinical Oncology consultants, you will be responsible for the comprehensive management of GI malignancies
Candidates should possess prior knowledge of radiotherapy planning and demonstrate enthusiasm for Clinical Oncology. This role offers an exciting blend of clinical exposure and research innovation.
​
Post 2 – Medical Oncology Targeted Therapy in Cholangiocarcinoma
Research Objectives: This role presents a unique opportunity to investigate resistance pathways and design targeted interventions for FGFR2-driven malignancies.
Requirements: We are seeking candidates with a background in medical oncology demonstrating enthusiasm and a drive for innovative research. This role offers a stimulating blend of clinical care and cutting-edge research opportunities. If you are passionate about advancing the understanding and treatment of cholangiocarcinoma, we encourage you to apply.
​
Click on the button below to find out more
​
Application Deadline: 7th May 2024
STUDY ON CLINICAL DECISION SUPPORT SYSTEMS
Do you use clinical decision support systems?
If so, please see the attached invitation below to participate in an interview study conducted by researchers from the University of Leeds, to explore the views of health professionals towards using data-driven clinical decision support tools in their clinical practice.
Background: Recent advances in technology, statistical and machine learning techniques, mean it is possible to analyse large quantities of data about multiple patients. There are many new data-driven clinical decision support tools being developed using these techniques, but as yet only a few are available for clinical use. Not much is known yet about how healthcare practitioners feel about using such tools, whether they trust them, or how useful they find them.
Approval: This study has been approved by the University of Leeds School of Medicine Research Ethics Committee, reference MREC 22-107.
CRUK EARLY DIAGNOSIS CONFERENCE 2024
4th & 5th June 2024
The Eastside Rooms, Birmingham
​
This in-person conference promises bring together the cancer community in the UK, showcasing the latest early diagnosis evidence around the theme ‘Driving Evidence into Practice’.
​
The call for abstracts across the following themes is open until 20th March 2024. A small number of bursaries are available for early career researchers.
1. Implementation and optimisation of screening
2. Supporting timely help-seeking presentation by the public
3. Optimising the patient referral journey from primary to secondary care
4. Improving pathways and service models to support timely cancer diagnosis
5. Translation of innovation – new diagnostic tests and tools supporting the earlier detection of cancer
6. Other e.g. early diagnosis epidemiology
​
To find out more, visit their website by clicking the button below, or email edconference@cancer.org.uk for more information
MEDICINE AT THE CRICK
INFLAMMATION AND CANCER PROMOTION: REVISITING BERENBLUM
Thursday 6th June 2024, 14:00-17:45
​
Hybrid event taking place virtually and in person, organised by The Francis Crick Institute, London
​
'Our Medicine at the Crick event series showcases major advances in biomedical science and raises awareness of the medical implications of major scientific advances. Interested members of the wider UK biomedical community are invited to attend.
​
More about the event
This 14th edition of Medicine at the Crick will be hosted by Charlie Swanton (The Francis Crick Institute.)
Increasing evidence suggests humans are a patchwork of mutant clones. Indeed, it is estimated that a healthy 60-year-old will have over a 100 million mutant clones with oncogenic mutations, yet cancer is not an inevitable consequence of ageing. These data suggest that oncogenic mutations may be necessary for tumour initiation, but they may not be sufficient. In keeping with this, Isaac Berenblum provided evidence that tumour initiation in mouse models was a two-step process. The first, we now know involves the acquisition of an oncogenic mutation, the second, exposure to an inflammatory stimulator such as TPA. The two together are required for tumour formation. Increasing evidence in pancreas, melanoma, glioma, lung cancer and mesothelioma suggest similar initiation/promotion mechanisms are required for tumour initiation. These discoveries have important implications for preventative medicines targeting the first steps in tumour evolution. This Medicine at the Crick event will review the state-of-the-art evidence supporting the Berenblum initiator-promoter model and explore how this knowledge may impact new efforts to prevent tumour initiation and open up a new field of molecular cancer prevention.
Programme
​
Speakers and panellists include: Dr Direna Alonso-Curbelo (Institute for Research in Biomedicine Barcelona), Dr William Hill (The Francis Crick Institute), Prof Simona Parrinello (UCL Cancer Insitute), Prof Richard Marais (Oncodrug Ltd) and Prof Allan Balmain (UCSF Helen Diller Family Comprehensive Cancer Center) and Dr Ilaria Malanchi (The Francis Crick Institute).
Lectures will be followed by a Q&A panel discussion and a networking reception for in person attendees until 19:00.
You can find a more detailed provisional programme here.
Registration
​
Visit our webpages for further details including a more detailed programme, and register via Eventbrite to order a free virtual or in person ticket for the event.
Please send any questions to: medicine-at-crick@crick.ac.uk
Please feel free to circulate this information among any colleagues who may be interested.
We look forward to welcoming you to our Medicine at the Crick event.
With all good wishes,
Professor Sir Peter Ratcliffe FRS, Director of Clinical Research
Professor Charlie Swanton, Deputy Director of Clinical Research'
RCR CLINICAL ONCOLOGY TRAINEE RESEARCH NETWORK
The trainee members of the Clinical Oncology Academic Committee provide monthly email updates on external funding, fellowship and lectureship opportunities and relevant meetings and training courses in order to encourage the number and quality of research-active and academic Clinical Oncologists to members of the Clinical Oncology Trainee Research Network.
​
How to get involved
​
To register for your interest and subscribe to these monthly updates, click on the button below.
UK EARLY CAREERÂ RESEARCHERS IN CANCER RELAUNCH
Message from the UK ECRC December 2023
'We have exciting news to share regarding the future of our multidisciplinary community. In light of the NCRI winding down, we are thrilled to announce the relaunch of our forum as the UK Early Career Researchers in Cancer (UK ECRC) group! 🎉🎉🎉
​
Upcoming Opportunities!
We have been working hard behind the scenes to relaunch the forum and as we embark on this new chapter, we have some exciting opportunities lined up for our multidisciplinary members.
We are officially relaunching at the NOTCH Symposium in February next year, where we will have the chance to connect, share ideas, and explore new possibilities together!
We have been forging novel and exciting partnerships with national and international multidisciplinary organisations, which we will be updating you on very soon. This will lead to a plethora of future opportunities for our members.
Upcoming roles!
In the near future, we will be recruiting new positions within our committee and working groups. Please watch this space! 👀
What do I need to do to stay part of the group?
Nothing! You do not need to re-register to continue within the group, and it remains a free resource for ECRs across the UK.
Who and how can others join the group?
Any multidisciplinary professionals with an interest in cancer research, who consider themselves early in their research career, can apply to join this group. Please use the following link for new members to join: ✨ https://forms.office.com/r/irThJTVkmu ✨
How to Stay Engaged? 💻
· Follow us on X: @UKECRC
· Contribute to upcoming opinion surveys – these will help us to help you and will help us identify engaged members to consider for committee roles!
· Keep an eye on your inbox for updates and invitations to upcoming events.
· Look out for our future networking platform, where you can connect with fellow members and stay informed about the latest news.
Your Data and Privacy
Your email address and the data you provided upon signing up (including your current role and research interests) have been obtained from the NCRI following full approval. We want to reassure you that we have sought advice from the Information Commissioner's Office (ICO), and your data is still being kept privately and securely.
What if I want to leave the group?
We understand your circumstances may have changed and we respect your privacy. If you wish to opt out at any time, you can do so by clicking on https://forms.office.com/r/WkAaHSRMwi
We are incredibly grateful for your continued support, and we look forward to the vibrant discussions and collaborations that lie ahead. If you have any questions or concerns, or want to get more involved in the group, please feel free to reach out.'
INDUSTRY RESEARCH FELLOWSHIP OPPORTUNITY WITH BIONTECH FOR ONCOLOGY TRAINEES
​
In July 2023, BioNTech signed a long-term partnership agreement with the UK, with the goal of working together to develop new cancer therapies for the benefit of NHS patients. This includes an accelerated clinical trials program supported by NIHR and NHS England, agreeing to deliver 10,000 cancer vaccines to patients in the UK by 2030. BioNTech have a diverse portfolio of trials in cancer vaccines and next generation immunotherapies, currently being brought to the UK. With this in mind, it is an exciting time to be involved in these latest technologies and trials and this role offers a unique opportunity to be at the forefront of the national cancer vaccine advance.
BioNTech are expanding their UK team and it is an exciting time to be involved in the national cancer vaccine advance. Research interest and experience is important, and whilst previous industry experience is a bonus it is certainly not required. The role as a medical science liaison includes serving as the link between trial investigators and BioNTech, but also supporting global trials teams with activities from clinical development and early protocol discussion, to overseeing regulatory approvals and inputting on general strategy for the UK partnership and initiatives such as the Cancer Vaccine Launchpad.
This role is primarily remote, and ideal as an out of programme experience for medical or clinical oncologists. Duration is flexible, but a minimum of 1 year (2-3 years recommended.)
​
If interested, please contact rosie.mew@biontech.co.uk